Zydus Cadila has received an approval from the US FDA to market Ramipril capsules in the strengths of 1.25 mg, 5 mg, and 10 mg. The drug falls in the anit-hypertensive segment. The sale of Ramipril capsules as per NDC was estimated at US$ 1.06 billion.

The Group now has 41 approvals and has so far filed 79 ANDAs since the commencement of filing process in 2003-04.